![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
On March 4 2011, the SGC hosted a workshop to discuss the mechanisms of BMP/TGF-β signalling and to review the opportunities and challenges for drug discovery. TGF-β superfamily ligands (TGF-β, nodal, activins, myostatin, GDFs and BMPs) modulate the growth of stem cells and tissues including muscle, bone, adipose and the vasculature. In recent years, TGF-β superfamily antagonists have entered the clinic for the potential treatment of musculoskeletal, metabolic and cancer-related diseases.
The SGC meeting held in the Nuffield Orthopaedic Centre in Oxford UK brought together scientists from seven different countries, including seven industrial organizations and seven academic institutions. Themes addressed through a series of short talks, included SGC crystal structures, small molecule screens and applications, in vivo reporter lines, clinical genetics, receptor dynamics, Smad and non-Smad signalling pathways, transcriptional activation and EMT/tumorigenesis. The final speaker session included perspectives from industry on the different challenges associated with targeting BMP, activin and TGF-β receptor kinases.
The workshop concluded with an open discussion session to consider future questions and directions. From this session the following points were captured:
Read more about the structures: 3MY0, 3H9R, 3MTF, 3OOM, 3MDY, 3Q4T, 3G2F